HRTX
NASDAQ
US
Heron Therapeutics, Inc. - Common Stock
$0.80
▲ +$0.00
(+0.00%)
Vol 906K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$238.4M
ROE
-117.5%
Margin
-8.8%
D/E
216.16
Beta
1.27
52W
$1–$3
Wall Street Consensus
9 analysts · Apr 20262
Strong Buy
6
Buy
1
Hold
0
Sell
0
Strong Sell
88.9%
Buy Rating
Price Chart
Similar Stocks
ABOS
Acumen Pharmaceuticals Inc
$127.8M
VTVT
vTv Therapeutics Inc
$167.1M
KALA
KALA BIO Inc
$12.2M
IMUX
Immunic Inc
$64.2M
TNYA
Tenaya Therapeutics Inc
$154.0M
UNCY
Unicycive Therapeutics Inc
$124.0M
DTIL
Precision BioSciences Inc
$100.1M
FATE
Fate Therapeutics Inc
$113.3M
SPRO
Spero Therapeutics Inc
$131.3M
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.02 | $-0.02 | +$0.00 |
| Sep 2025 | $-0.02 | $-0.04 | $-0.02 |
| Jun 2025 | $-0.01 | $-0.02 | $-0.01 |
| Mar 2025 | $-0.01 | $0.01 | +$0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | $40.8M | $38.9M | $37.2M | $38.2M | $40.6M |
| Net Income | $3.7M | $2.6M | -$2.4M | -$17.5M | -$3.0M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -627.3% | -627.3% | -627.3% | -117.5% | -117.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -6.4% | -0.6% | -0.6% | -0.6% | -8.8% | -8.8% |
| Gross Margin | 73.5% | 74.6% | 74.6% | 74.6% | 73.9% | 73.9% |
| D/E Ratio | — | 1097.79 | 1097.79 | 1097.79 | 216.16 | 216.16 |
| Current Ratio | 0.82 | 0.82 | 0.82 | 0.82 | 2.56 | 2.56 |
Key Ratios
ROA (TTM)
-5.7%
P/S (TTM)
1.54
P/B
21.9
EPS (TTM)
$-0.08
CF/Share
$-0.93
Rev Growth 3Y
+18.7%
52W High
$2.68
52W Low
$1.00
$1.00
52-Week Range
$2.68
Financial Health
Free Cash Flow
-$9.2M
Net Debt
$112.0M
Cash
$28.6M
Total Debt
$140.6M
As of Dec 31, 2025
How does HRTX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
HRTX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
1.5
▼
88%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
21.9
▲
788%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
HRTX profitability vs Biotechnology peers
ROE
-117.5%
▼
75%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-8.8%
▲
97%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
73.9%
▼
6%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-5.7%
▲
88%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
HRTX financial health vs Biotechnology peers
D/E ratio
216.2
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
2.6
▼
42%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.3
▲
31%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
HRTX fundamentals radar
HRTX
Peer median
Industry
HRTX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
HRTX vs peers: key metrics
Latest News
No related news yet